Khorana、PROTECHT与5-SNP评分在癌症患者静脉血栓栓塞预测中的评估
该研究比较了Khorana评分与临床PROTECHT评分及多基因5-SNP评分在荷兰CPCT-02研究患者中的预测性能。2729例晚期实体瘤患者随访6个月,160例(5.9%)发生VTE。三种评分的6个月时间依赖c指数分别为0.57、0.60和0.54,高危组VTE风险约为低危组的2倍,但敏感性均较低,多数VTE患者未被识别。
要点
- Khorana、PROTECHT和5-SNP评分的6个月c指数均较低(0.54-0.60)。
- 高危组VTE风险约为低危组的2倍,但敏感性仅14.9%-28.9%。
- 多数6个月内发生VTE的癌症患者未被这些评分识别。
核心结论
- PROTECHT或5-SNP评分的预测性能并不优于Khorana评分。
- 多数6个月随访期间发生VTE的癌症患者未被这些评分识别。
研究设计与样本
- 回顾性收集荷兰CPCT-02研究中2729例计划接受系统性治疗的晚期实体瘤患者的VTE及危险因素数据。
- 随访6个月,采用时间依赖c指数评估整体判别性能,并在竞争风险模型中进行二分类评估。
主要发现
- 共160例(5.9%)患者在随访期间发生VTE。
- Khorana、PROTECHT和5-SNP评分的6个月时间依赖c指数分别为0.57(95%CI:0.55-0.60)、0.60(95%CI:0.57-0.62)和0.54(95%CI:0.51-0.57)。
- 二分类评分将9.6%、16.8%和9.5%的患者归为高危。
- 高危患者VTE风险约为低危患者的2倍:Khorana评分SHR 1.9(95%CI:1.3-3.0),PROTECHT评分SHR 2.1(95%CI:1.5-3.0),5-SNP评分SHR 1.7(95%CI:1.03-2.8)。
- 6个月敏感性分别为16.6%(95%CI:10.5-22.7)、28.9%(95%CI:21.5-36.3)和14.9%(95%CI:8.5-21.2)。
临床怎么用
- 在晚期实体瘤患者中,Khorana评分仍可作为VTE风险分层工具,但需认识到其识别高危患者的敏感性有限。
- PROTECHT和5-SNP评分未显示优于Khorana评分,暂不推荐替代Khorana评分用于临床VTE风险预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Khorana score is a validated tool to identify cancer patients at higher risk of venous thromboembolism (VTE). OBJECTIVE: We compared its predictive performance to that of the clinical PROTECHT and the polygenic 5-SNP scores in patients who participated in the Dutch CPCT-02 study. PATIENTS/METHODS: Data on VTE and its risk factors were retrospectively collected for 2729 patients with advanced stage solid tumors planned for systemic cancer treatment. Patients were followed for 6 months. Overall discriminatory performance of the scores was evaluated by time-dependent c-indices. The scores were additionally evaluated dichotomously in competing risk models. RESULTS: A total of 160 (5.9%) patients developed VTE during follow-up. Time-dependent c-indices at 6 months for the Khorana, PROTECHT, and 5-SNP scores were 0.57 (95% confidence interval [CI]: 0.55-0.60), 0.60 (95% CI: 0.57-0.62), and 0.54 (95% CI: 0.51-0.57), respectively. The dichotomous scores classified 9.6%, 16.8%, and 9.5% as high-risk, respectively. VTE risk was about 2-fold higher among high-risk patients than low-risk patients for the Khorana (subdistribution hazard ratio [SHR] 1.9, 95% CI: 1.3-3.0), PROTECHT (SHR 2.1, 95% CI: 1.5-3.0), and 5-SNP scores (SHR 1.7, 95% CI: 1.03-2.8). The sensitivity at 6 months was 16.6% (95% CI: 10.5-22.7), 28.9% (95% CI: 21.5-36.3), and 14.9% (95% CI: 8.5-21.2), respectively. CONCLUSIONS: Performance of the PROTECHT or 5-SNP score was not superior to that of the Khorana score. The majority of cancer patients who developed VTE during 6-month follow-up were not identified by these scores. Future directions for studies on cancer-associated VTE prediction may include combined clinical-genetic scores.
引用
- Guman NAM, van Geffen RJ, Mulder FI, et al. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. J Thromb Haemost. 2021. PMID: 34409743. doi:10.1111/jth.15503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。